Severe mental illness and European COVID-19 vaccination strategies

Livia J.  De Picker; Benedetta  Vai; Marisa  Casanova Dias; Igor  Branchi; Francesco Benedetti; Michael E.  Benros; Alessandra Borsini; Juan Carlos  Leza; Hillka  Kärkkäinen; Miia  Männikkö; Carmine M. Pariante; Ekin  Sönmez Güngör; Anna  Szczegelniak; Ryad  Tamouza; Afra  van der Markt; Paolo Fusar-Poli; Julian  Beezhold; Marion  Leboyer

doi:10.1016/S2215-0366(21)00046-8

Severe mental illness and European COVID-19 vaccination strategies

Livia J. De Picker , Benedetta Vai, Marisa Casanova Dias , Igor Branchi , Francesco Benedetti, Michael E. Benros , Alessandra Borsini, Juan Carlos Leza , Hillka Kärkkäinen, Miia Männikkö, Carmine M. Pariante, Ekin Sönmez Güngör , Anna Szczegelniak , Ryad Tamouza , Afra van der Markt, Paolo Fusar-Poli, Julian Beezhold , Marion Leboyer

Research output: Contribution to journal › Comment/debate › peer-review

58 Citations (Scopus)

224 Downloads (Pure)

Original language	English
Pages (from-to)	356-359
Number of pages	4
Journal	The Lancet Psychiatry
Volume	8
Issue number	5
Early online date	17 Feb 2021
DOIs	https://doi.org/10.1016/S2215-0366(21)00046-8
Publication status	Published - May 2021

Access to Document

10.1016/S2215-0366(21)00046-8

PIIS2215036621000468Accepted author manuscript, 154 KB
Severe mental illness and European COVID-19 vaccination strategies_Final

Cite this

De Picker , L. J., Vai, B., Casanova Dias , M., Branchi , I., Benedetti, F., Benros , M. E., Borsini, A., Leza , J. C., Kärkkäinen, H., Männikkö, M., Pariante, C. M., Sönmez Güngör , E., Szczegelniak , A., Tamouza , R., van der Markt, A., Fusar-Poli, P., Beezhold , J., & Leboyer , M. (2021). Severe mental illness and European COVID-19 vaccination strategies. The Lancet Psychiatry, 8(5), 356-359. https://doi.org/10.1016/S2215-0366(21)00046-8

@article{7e9b1f697d2b42a4b0292891d24a10a4,

title = "Severe mental illness and European COVID-19 vaccination strategies",

author = "{De Picker}, {Livia J.} and Benedetta Vai and {Casanova Dias}, Marisa and Igor Branchi and Francesco Benedetti and Benros, {Michael E.} and Alessandra Borsini and Leza, {Juan Carlos} and Hillka K{\"a}rkk{\"a}inen and Miia M{\"a}nnikk{\"o} and Pariante, {Carmine M.} and {S{\"o}nmez G{\"u}ng{\"o}r}, Ekin and Anna Szczegelniak and Ryad Tamouza and {van der Markt}, Afra and Paolo Fusar-Poli and Julian Beezhold and Marion Leboyer",

note = "Funding Information: This paper has been developed collaboratively and has received endorsements from the European College of Neuropsychopharmacology, European Psychiatric Association, European Federation of Associations of Families of People with Mental Illness, Global Alliance of Mental Illness Advocacy Networks-Europe, and European Union of Medical Specialists, Section of Psychiatry. The authors would like to express their utmost gratitude to our network of local representatives who helped to identify, collect and review the national strategy documents, and provided additional information derived from their personal clinical experience and the national psychiatric associations: Pavel Trancik (Czech Republic), Paula Mustonen (Finland), J{\"o}rdis Rausch (Germany), Thanos Khanellopoulos (Greece), Zetti Azvee (Ireland), Liene Berze (Latvia), Giovanni Grech (Malta), Morten Svendal Hatlen (Norway), Miguel Bajouco (Portugal), Celso Arango and Eduard Vieta (Spain), Stanko Medic, Amelie Kjellstenius, and Tove Mogren (Sweden). LJDP is a member of the European College of Neuropsychopharmacology Immunopsychiatry Thematic Working Group and the European Psychiatriac Association Committee on Education. LJDP reports grants from Boehringer-Ingelheim and Janssen R&D, outside the submitted work. MCD is vice president for Continuing Medical Education at the European Union of Medical Specialists, Section of Psychiatry. CMP received research and consultancy funding from Johnson & Johnson (2012–18) and Boehringer Ingelheim (2020) and is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer's Disease consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck, and Pfizer, outside the submitted work. CMP is also funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King's College London, and by a NIHR Senior Investigator Award. PF-P reports personal fees from Menarini, Angelini, and Lundbeck, outside the submitted work. ML reports personal fees from Janssen and Sanofi; grants from Otsuka, Lundbeck, and Roche, outside the submitted work. All other authors declare no competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = may,

doi = "10.1016/S2215-0366(21)00046-8",

language = "English",

volume = "8",

pages = "356--359",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier",

number = "5",

}

De Picker , LJ, Vai, B, Casanova Dias , M, Branchi , I, Benedetti, F, Benros , ME, Borsini, A, Leza , JC, Kärkkäinen, H, Männikkö, M, Pariante, CM, Sönmez Güngör , E, Szczegelniak , A, Tamouza , R, van der Markt, A, Fusar-Poli, P, Beezhold , J & Leboyer , M 2021, 'Severe mental illness and European COVID-19 vaccination strategies', The Lancet Psychiatry, vol. 8, no. 5, pp. 356-359. https://doi.org/10.1016/S2215-0366(21)00046-8

TY - JOUR

T1 - Severe mental illness and European COVID-19 vaccination strategies

AU - De Picker , Livia J.

AU - Vai, Benedetta

AU - Casanova Dias , Marisa

AU - Branchi , Igor

AU - Benedetti, Francesco

AU - Benros , Michael E.

AU - Borsini, Alessandra

AU - Leza , Juan Carlos

AU - Kärkkäinen, Hillka

AU - Männikkö, Miia

AU - Pariante, Carmine M.

AU - Sönmez Güngör , Ekin

AU - Szczegelniak , Anna

AU - Tamouza , Ryad

AU - van der Markt, Afra

AU - Fusar-Poli, Paolo

AU - Beezhold , Julian

AU - Leboyer , Marion

N1 - Funding Information: This paper has been developed collaboratively and has received endorsements from the European College of Neuropsychopharmacology, European Psychiatric Association, European Federation of Associations of Families of People with Mental Illness, Global Alliance of Mental Illness Advocacy Networks-Europe, and European Union of Medical Specialists, Section of Psychiatry. The authors would like to express their utmost gratitude to our network of local representatives who helped to identify, collect and review the national strategy documents, and provided additional information derived from their personal clinical experience and the national psychiatric associations: Pavel Trancik (Czech Republic), Paula Mustonen (Finland), Jördis Rausch (Germany), Thanos Khanellopoulos (Greece), Zetti Azvee (Ireland), Liene Berze (Latvia), Giovanni Grech (Malta), Morten Svendal Hatlen (Norway), Miguel Bajouco (Portugal), Celso Arango and Eduard Vieta (Spain), Stanko Medic, Amelie Kjellstenius, and Tove Mogren (Sweden). LJDP is a member of the European College of Neuropsychopharmacology Immunopsychiatry Thematic Working Group and the European Psychiatriac Association Committee on Education. LJDP reports grants from Boehringer-Ingelheim and Janssen R&D, outside the submitted work. MCD is vice president for Continuing Medical Education at the European Union of Medical Specialists, Section of Psychiatry. CMP received research and consultancy funding from Johnson & Johnson (2012–18) and Boehringer Ingelheim (2020) and is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer's Disease consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck, and Pfizer, outside the submitted work. CMP is also funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King's College London, and by a NIHR Senior Investigator Award. PF-P reports personal fees from Menarini, Angelini, and Lundbeck, outside the submitted work. ML reports personal fees from Janssen and Sanofi; grants from Otsuka, Lundbeck, and Roche, outside the submitted work. All other authors declare no competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/5

Y1 - 2021/5

UR - http://www.scopus.com/inward/record.url?scp=85104324869&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(21)00046-8

DO - 10.1016/S2215-0366(21)00046-8

M3 - Comment/debate

SN - 2215-0366

VL - 8

SP - 356

EP - 359

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 5

ER -

Severe mental illness and European COVID-19 vaccination strategies

Access to Document

Other files and links

Cite this